ATS GUIDELINES Bundle

Community Acquired Pneumonia in Adults

American Thoracic Society Quick-Reference GUIDELINES Apps

Issue link: http://eguideline.guidelinecentral.com/i/1194279

Contents of this Issue

Navigation

Page 1 of 11

2 Key Points ➤ This guideline addresses the clinical entity of pneumonia that is acquired outside of the hospital setting in patients in the U.S. who have not recently completed foreign travel and who do not have an immunocompromising condition. ➤ Antibiotic recommendations for the empiric treatment of community-acquired pneumonia (CAP) are based on selecting agents effective against the major treatable bacterial causes of CAP. • Traditionally, these bacterial pathogens include Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Staphylococcus aureus, Legionella species, Chlamydia pneumoniae, and Moraxella catarrhalis. ➤ In addition, the emergence of multidrug-resistant pathogens, including methicillin-resistant S. aureus (MRSA) and Pseudomonas aeruginosa require separate recommendations when the risk of each of these pathogens is elevated. ➤ Other, far less common, multidrug-resistant Enterobacteriaceae can cause CAP, including organisms producing extended- spectrum beta-lactamase (ESBL). Those organisms are effectively covered by P. aeruginosa strategies and are therefore not otherwise mentioned. ➤ Bacterial pathogens often co-exist with viruses, and there is no current diagnostic test accurate enough or fast enough to determine that CAP is due solely to a virus at the time of presentation. Therefore, our initial recommendations are to treat empirically for possible bacterial infection or co-infection.

Articles in this issue

view archives of ATS GUIDELINES Bundle - Community Acquired Pneumonia in Adults